Previous 10 | Next 10 |
Oncorus (ONCR): Q4 GAAP EPS of -$0.56 misses by $0.08.Cash and cash equivalents of $130.3MPress Release For further details see: Oncorus EPS misses by $0.08
2020 marked year of notable progress for Oncorus. Key highlights included: Transitioned to clinical-stage company with initiation of Phase 1 clinical trial of lead viral immunotherapy candidate, ONCR-177, for the treatment of solid tumors Announced clinical trial collaboration a...
The company is using engineered herpes simplex viruses and engineered synthetic viruses in oncology. The stock doubled after the IPO, then pulled back close to the IPO price and is rebounding. Phase 1 monotherapy data for ONCR-177 in cancers like breast, melanoma and head and neck...
Oncorus (ONCR) has priced 3M common shares offering at $19/share, for expected gross proceeds of $57M.Underwriters' over-allotment is an additional 450K shares.Offering is expected to close on February 17.Previously: Oncorus proposes 3M share public offering (Feb. 9) For further details see...
CAMBRIDGE, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to transform outcomes for cancer patients, today announced the pricing of its underwritten publi...
Oncorus Inc. (ONCR) has proposed an underwritten public offering of 3M shares.Oncorus also expects to grant the underwriters a 30-day option to purchase up to an additional 450K shares.Jefferies, Evercore ISI, and Piper Sandler are joint book-runners.Oncorus shares are down 2.1% to ...
CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Oncorus, Inc. (Nasdaq: ONCR), a clinical stage biopharmaceutical company developing next-generation, systemically active viral immunotherapies to transform outcomes for cancer patients, today announced it has commenced an underwritten publ...
Oncorus Inc.'s share price has risen by over 120% in about three months of listing. ONCR's novel technology is still a reason to consider the stock as an investment in emerging biopharmaceutical, but the upside seems to be limited from the current levels. Buying the stock at level...
Oncorus (ONCR) announces preclinical data supporting the clinical development of its lead oncolytic Herpes Simplex Virus (oHSV) clinical candidate, ONCR-177.ONCR-177 demonstrated potent and durable antitumor activity in multiple immune-competent tumor models.Preclinical findings show that ONC...
-- Preclinical findings show that ONCR-177’s systemic antitumor immunity is driven by its five complementary immunomodulatory transgene payloads and retention of γ 34.5 -- -- Complete and durable tumor regression and protective antitumor memory observed in mu...
News, Short Squeeze, Breakout and More Instantly...
iClick Interactive Asia Group Limited (ICLK) is expected to report for quarter end 2023-09-30 Applied Minerals Inc (AMNL) is expected to report for quarter end 2023-09-30 Banco Do Brasil S.A. ADR (BDORY) is expected to report for Q3 2023 Rubius Therapeutics Inc. (RUBY) is expected to ...
American Bio Medica Corp. (ABMC) is expected to report for quarter end 2023-09-30 Surgalign Holdings Inc. (SRGAQ) is expected to report for quarter end 2023-09-30 MillerKnoll Inc. (MLKN) is expected to report $0.52 for Q2 2024 Ping AN Insurance (Group) Co. of China, Ltd. ADR - Level I...
Epiroc AB ADR (EPOKY) is expected to report for Q3 2023 Sysmex Corporation ADR (SSMXY) is expected to report for Q2 2024 Streamline Health Solutions Inc. (STRM) is expected to report for Q1 2024 Helix Biopharma Corp. (HBPCF) is expected to report for Q2 2024 Standard Chartered plc...